Cohance Lifesciences responds to NSE inquiry on increased trading volume, citing Regulation 30 of SEBI Listing Regulations.
Company confirms no pending price-sensitive information requiring disclosure that could impact scrip price/volume.
Attributes the volume movement to prevailing market-driven conditions and not company-specific developments.
Reaffirms regular compliance with UPSI notification requirements under SEBI Listing Regulations.